Celyad Oncology SA CLYYF
OTC PK
| 06/30/2026 | 03/31/2026 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | 0.00% | -- | |||
| Gross Profit | 0.00% | -156.10% | |||
| SG&A Expenses | -0.58% | -81.81% | |||
| Depreciation & Amortization | -0.79% | -- | |||
| Other Operating Expenses | -0.58% | 113.94% | |||
| Total Operating Expenses | -0.59% | 156.74% | |||
| Operating Income | 0.59% | -156.55% | |||
| Income Before Tax | 0.59% | -127.00% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 0.59% | -127.00% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 0.59% | -127.00% | |||
| EBIT | 0.59% | -156.55% | |||
| EBITDA | 0.59% | -154.47% | |||
| EPS Basic | 0.63% | -126.60% | |||
| Normalized Basic EPS | 1.01% | -157.23% | |||
| EPS Diluted | 0.63% | -130.80% | |||
| Normalized Diluted EPS | 1.01% | -166.44% | |||
| Average Basic Shares Outstanding | 0.00% | 1.43% | |||
| Average Diluted Shares Outstanding | 0.00% | -12.42% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||